Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.5%

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares traded up 7.5% during trading on Monday . The stock traded as high as $18.63 and last traded at $18.47. 88,659 shares traded hands during trading, a decline of 61% from the average session volume of 228,233 shares. The stock had previously closed at $17.18.

Analyst Upgrades and Downgrades

Separately, Mizuho began coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price target on the stock.

Enliven Therapeutics Stock Up 3.6 %

The stock has a market cap of $832.75 million, a price-to-earnings ratio of -8.44 and a beta of 1.06. The company’s fifty day moving average is $17.12 and its two-hundred day moving average is $14.50.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In related news, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total value of $7,500,000.00. Following the completion of the sale, the insider now directly owns 771,983 shares of the company’s stock, valued at $11,579,745. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, COO Anish Patel sold 4,875 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $15.11, for a total transaction of $73,661.25. Following the transaction, the chief operating officer now directly owns 12,347 shares in the company, valued at $186,563.17. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total transaction of $7,500,000.00. Following the completion of the sale, the insider now owns 771,983 shares of the company’s stock, valued at approximately $11,579,745. The disclosure for this sale can be found here. Insiders have sold 731,536 shares of company stock worth $12,710,141 over the last three months. Insiders own 45.80% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. AJOVista LLC acquired a new position in Enliven Therapeutics in the 4th quarter valued at $28,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth about $66,000. Exchange Traded Concepts LLC raised its holdings in Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after purchasing an additional 2,208 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics in the third quarter valued at about $157,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after buying an additional 1,029 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.